Aiforia Technologies Plc – Managers’ Transactions – Tuomas Tenkanen

Aiforia Technologies Plc MANAGERS’ TRANSACTIONS December 12, 2025 01:00 p.m. EET

Aiforia Technologies Plc has received a notification from Tuomas Tenkanen, Aiforia Technologies Plc's Board member, of a transaction made with Aiforia Technologies Plc’s financial instrument, according to the Article 19 of EU Market Abuse Regulation.

Detailed information about the transaction is given here under.

____________________________________________

Aiforia Technologies Oy - Managers' Transactions

____________________________________________

Person subject to the notification requirement

Name: TJT Technologies Oy

Position: Chief Executive Officer

(X) Legal person (1):Person Discharging Managerial Responsibilities In Issuer

Name: Tuomas Tenkanen

Position: Member of the Board

Issuer: Aiforia Technologies Oy

LEI: 743700TJRVBX7420Y723

Notification type: INITIAL NOTIFICATION

Reference number: 133886/4/4

____________________________________________

Transaction date: 2025-12-10

Outside a trading venue

Instrument type: SHARE

ISIN: FI4000507934

Nature of transaction: SUBSCRIPTION

Transaction details

(1): Volume: 283979 Unit price: 2.106 EUR

Aggregated transactions (1):

Volume: 283979 Volume weighted average price: 2.106 EUR

Further inquiries

Veli-Matti Parkkonen, CFO, Aiforia Technologies Plc, tel. +358405009878 https://investors.aiforia.com/

Certified Adviser

UB Corporate Finance Ltd

ubcf@unitedbankers.fi

About Aiforia 

Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers advanced software solutions that elevate diagnostic capabilities in image analysis, empowering remarkable medical discoveries both today and in the future. With thousands of AI models developed for research use and several diagnostic solutions deployed, Aiforia is making a significant impact on pathology and healthcare. In Europe, Aiforia is the leading provider of CE-IVD marked AI-powered solutions for digital pathology.

Founded in 2013, Aiforia is a publicly traded company with a global presence and thousands of users worldwide. Headquartered in Helsinki, Finland, the company also operates subsidiaries in the United States and France, and maintains a network of local representatives across Europe and North America. Aiforia’s diverse team includes experienced AI and software developers, pathologists, medical scientists, and a dedicated commercial team. Together, they are transforming pathology through AI, enabling better care for every patient. 

Find out more at www.aiforia.com